Floatz logo

Irinotecan

Multiple Myeloma

OHSU Knight Cancer InstituteSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
59/ 100

Competitive context

343 Active assets in the Multiple Myeloma cohort.

Asset / SponsorPhaseRating
Inno-206
GlaxoSmithKline
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Janssen Research & Development, LLC
Phase 4BB
PREDNISONE TABLETS
GlaxoSmithKline
Phase 4BB
Thalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
DEXAMETHASONE
Universitätsklinikum Hamburg-Eppendorf
Phase 4BB

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →